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B5 Economic Aspects of Intermittent Claudication
Cost data on the diagnosis or treatment of claudication appear to be very scarce in the medical
and the economic literature. This is partly because analyses of claudicants have presented results
on the global cost of tile disease (including all types of patients) or instead of the Fontaine clas-
sification have used some other grouping method that renders interpretation of the results diffi-
cult. In other cases, the results concerned small numbers of patients with minimal description of
the sampling methods and little external validity. In the results presented later in this document
and also in Economic Aspects of Acute Limb Ischemia and Economic Aspects of Critical Limb
Ischemia, costs are in US dollars with the European Euro in brackets, and local currencies were
converted based on tile Organisation for Economic Cooperation and Development (OECD)
purchasing power parity index. The year of the study is indicated.
B 5.1.1 Diagnostic Strategies
When assessing diagnostic strategies for patients with claudication, tile economic analysis can
focus on (1) tile most effective diagnostic strategy for a given individual, (2) the screening
strategy for the population at large, or (3) a subset of those presenting risk factors (eg, smoking
or cardiac disease). The investigations concern risk factors that could benefit from secondary
prevention-diseased peripheral arteries and the circulatory system (heart, brain)-to ascertain a
diagnosis, but more significantly, to plan tile most appropriate treatment, In countries where the
economic constraints have resulted in a limited supply of high-technology facilities, the optimal
use of these facilities is a major issue. Thus, an investigation may be extremely cost-effective if it
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results in ascertaining before an intervention whether a patient should be operated on. If not,
the benefits of deferring surgery are not only to the patient but also to another patient, who will
benefit from a freed time slot in the operating room. These opportunity costs are often difficult
to estimate.
When diagnosing risk factors in patients with IC, studies have been concerned with good clini-
cal practice but seldom with the economic evaluation of the diagnostic strategies recommended.
The cost-effectiveness analyses of screening strategies for hypercholesterolemia and high blood
pressure are relevant only in relation to the treatment strategies for risk factors. The interest of
screening for cardiovascular risk factors in a population in which the prevalence of atherosclero-
sis is high no longer needs to be demonstrated. There are few data on the cost-effectiveness of
investigating other arterial systems (cardiac and cerebral mostly) in patients with claudication.
The actual costs of diagnostic tests tor patients with IC were estimated in the vascular laboratory
of a US hospital.! Costs were estimated from the actual time spent by doctors and technicians,
equipment amortization and maintenance, supplies, and overheads. The authors computed the
costs tor their own institution and estimated a national average cost for 1993 derived from a sur-
vey of six academic US centers. The estimated cost of lower-extremity arterial duplex was $127
to $141 (Euro 118-131). The cost of plethysmography (any type) was estimated to be $63 to
$70 (Euro 59-65). These costs are highly dependent on the total number of procedures per-
formed per year; the underlying assumption of these cost computations was that the equipment
was operated at a 77% efficiency level, which represented 988 hours per machine annually.l
B 5.1.2 Cost of Treatment for Intermittent Claudication
A review of controlled clinical trials in patients with IC (stage II) reported the ambulatory costs
of drug treatment, which had been shown to improve the pain-free walking distance by at least
30% over placebo or absence of trcatment.Z Costs included the purchase of the drug and physi-
cian fees in 1994. The duration of treatment varied from 2 to 8 months. When considering the
effects of treatment on pain-free walking distance, it appeared that supervised exercise alone has
as good a result as most drugs, but at a $504 cost (Euro 468) per 24 months, including physio-
therapist fees.
The costs in 1994 ranged from $133 (Euro 124) for 3 months of treatment with oral naftidro-
furyl to $3,220 (Euro 2,995) for 4 weeks' infusion with alprostadil and are not proportional to
therapeutic efficacy- The variety of treatment duration and the lack of follow-up data make it
difficult to draw from this report any other conclusion than the good cost-effectiveness of
supervised exercise programs when compared with currently availabledrug therapy in this group
of patients. The costs of care for patients with claudication and conservative (medical) treatment
were estimated from a cohort study of 300 paticnts.f Out of these, one third eventually
required an invasive diagnostic or therapeutic procedure. The total health care costs during tile
2-year follow-up period were roughly $6,000 (Euro 5,580), three quarters of which was
accounted for by hospital costs.
A report on cost data drawn from two national databases in France gave an estimate of health
care costs (non-health care costs were not considered) for patients with IC in 1992. 4 The aver-
age hospital costs estimated from the charges to Social Security were $2,345 (Euro 2,181) per
patient. When considering patients with ambulatory treatment only, the costs were $1,100
(Euro 1,023) per patient, with 75% of this cost attributable to drug prescriptions. Other cost
items included consultations (20% of the total costs), follow-up tests, and hydrotherapy.
Critical Issue 17: Costs in relation to measure of effectiveness
There is a need to relate the costs of treating patients with intermittent claudicant to a
valid measure of effectiveness and for this to be gauged over time.
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It appears that supervised exercise programs yield good results on walking distance, unlike most
drugs, although the overall volume of drug prescriptions in these patients tends to be high. The
ambulatory costs, however, appear to be low by comparison with the costs incurred by patients
with IC when hospitalization is required.f A cost-effectiveness analysis showed that, compared
with exercise, treatment strategies that included angioplasty or both angioplasty and bypass
surgery improved quality-adjusted life expectancy.v However, the incremental cost-effectiveness
ratios were very high: $37,000 to 82,000 (Euro 34,410-76,260) per QALY gained for strate-
gies that included PTA and $202,000 to 779,000 (Euro 187,860-724,470) per QALY gained
for strategies that included both PTA and bypass surgery. In patients with a history of CAD, a
noninterventional (ie,.exercise only) strategy yielded the highest quality-adjusted life expectancy
at the lowest lifetime costs.?
The costs ofstent placement and PTA for iliac artery occlusive disease were documented by the
Dutch Iliac Stent Trial Study Group." Compared with primary stent placement, angioplasty with
selective stent placement yielded equivalent complication rates, patency results, and quality-of-life
outcomes and was cost saving. The health care costs of primary stent were $3,786 (Euro 3,521)
and increased to $3,990 (Euro 3,711 )when non-health care costs were added. For selective stent
placement, these costs were, respectively, $2,829 (Euro 2,631) and $3,033 (Euro 2,821).
Compared with angioplasty alone, which cost $2,139 (Euro 1,989) ($2,343 with non-health
care costs), angioplasty with selective stent placement was more expensive but yielded higher
patency results and quality-adjusted life expectancy, and under varying assumptions had an incre-
mental cost-effectiveness ratio ofless than $20,000 (Euro 18,600) per QALY gained.
Critical Issue 18: Comparison of relative cost-effectiveness between various Wes of treatment
There is a need for future studies to compare the relative cost-effectiveness over time
between various types of treatment: exercise programs, pharmacotherapy, other noninvasive
therapy, and endovascular or surgical intervention.
B 5.1.3 The Cost-effectiveness of Antiplatelet Therapy in Intermittent Claudication
Based on current evidence, treating patients with PAD with antiplatelet drugs appears to be
effective in reducing the risk of coronary and cerebrovascular eventsf in maintaining arterial and
graft:patency 9,10 and in slowing progression of disease.U From a cost-effectiveness point of
view, antiplatelet therapy is inexpensive ($30 per year for aspirin medication). In general, it is
well accepted that all patients with PAD, including those with IC, should be considered for
treatment with low-dose aspirin to reduce the risk of cardiovascular morbidity and mortality (see
Recommendation 28, p 583).
The Antiplatelet Trialists' Collaboration showed a nonsignificant reduction in vascular events
(vascular death, MI, stroke) with antiplatelet therapy in patients with IC of 10%, versus 12% in
approximately 3,300 patients (Table 30).8 Taking into account that this represents a mean of 26
months' scheduled antiplatelet therapy, we estimated the absolute benefit to be 9 events avoided
per 1,000 person-years (P¥s) of treatment. The risk reduction among those with claudication is
thus in the same order of magnitude as the risk reduction with secondary prevention in patients
with a prior MI, prior stroke or transient ischemic attack (TIA), or other high-risk groups. The
risk reduction among those with claudication was, however, far less than the risk reduction with
secondary prevention in patients with an acute MI (Table 30).
Although the risk reduction among those with IC was nonsignificant, results among patients
with PAD were pooled with the results from similar high-risk groups, excluding acute MI and
prior MI, stroke, or TIA. The pooled results showed a significant risk reduction of 7% versus
9%, and no significant heterogeneity could be shown across the subgroups. Excluding unstable
angina from the pooled results, there still remained a significant risk reduction of 6% versus 8%
and an absolute benefit of 20 events avoided per 1,000 PYs of treatment.
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Table 30. Summary of results from the Antiplatelet Trialists' Collaborationf
Betlefit
Mean Antiplatelettherapy Control ObserJ'ed- Benefit per
Patient Trials scbedflled -------- - --_._---- expected per 1,000
group 11 antipl&* events 11 risk (%) events n risl: (%) stratificd Var 1,000 PTs
Prior MI 11 27 1,331 9,877 13.5 1,693 9,914 17.1 -158.5 561.6 32 14
Acute Ml 9 1 992 9,388 10.6 1,348 9,385 14.4 -177.9 510.3 38 455
Prior stroke/ 18 33 1,076 5,837 18.4 1,301 5,870 22.2 -98.5 386.5 34 12
TlA
Other high 104 16 784 11,434 6.9 1,058 11,542 9.2 -134 352.5 23 17
risk
Claudication 22 26t 160 1,646 9.7 195 I,M9 11.8 -15.7 63.6 19 9
Low risk 3 62 652 14,608 4.5 708 14,604 4.8 -28.5 273.5 4 0.8
Abbreviation: PY, patient years.
*From Figure 3.8
t Weighted mean estimated from Appendix."
Table 31. Summary of results from the CAPRIE triaP2
Clopidogrel AsP!!ir~_ Relative ,-isk reduction.
Patimtgroup n even:rate (%) event rate (%) (95% confidence interval)
Stroke 6,431 7.15 7.71 7.3% (-5.7%-18.7%)
Myocardial infarction 6,302 5.03 4.84 -3.7% (-22.1%-12.0%)
Peripheral arterial disease 6,452 3.71 4.86 23.8% (8.9%- 36.2%)
The largest prospective randomized trial in patients with PAD regarding antiplatelet therapy was
the CAPRIE Trial.I? This trial enrolled over 19,000 patients, with over 6,000 having the prima-
ry diagnosis of PAD. This was confirmed by symptoms of claudication with a reduced ABPI, or
prior vascular surgery. Althogh the overall CAPRIE results were positive, showi.ng a statistically
favorable benefit of clopidogrel over aspirin i.npreventing cardiovascular events, the PAD sub-
group showed the greatest benefit. Thus, this study provides additional information regarding
the importance of using antiplatelet therapies in patients with cardiovascular disease. Patients
with PAD should all receive antiplatelct therapy to prevent the risk of Ml, stroke, and vascular
death. The data from the CAPRIE Trial (Table 31) suggest a dinically and statistically signifi-
cant better risk reduction with clopidogrel than with aspirin in patients with PAD.
The current evidence suggests that antiplatelet therapy in patients with IC, with the goal of
reducing the risk of coronary and cerebrovascular events, is comparable to secondary prevention
in those with a prior MI, stroke, or transient ischemic attack (TTA). Because secondary preven-
tion in patients with a prior MI, stroke, or TIA is considered cost-effective, and given the possi-
ble additional benefit of reducing the risk of vascular occlusion and progression of disease,
antiplate1et therapy (with low-dose enteric-coated aspirin and possibly clopidogrel in those who
cannot tolerate aspirin) appears cost-effective in patients with intermittent claudication (see also
Recommendation 28, p 583).
B 5.1.4 The Cost-effectiveness of Lipid Control in Intermittent Claudication
Patients with intermittent claudication present an increased risk for acute MI and stroke. 13,14
Cardiovascular event rates are close to those of patients who have suffered a recent MI (see A
2.5.3, Summary: Fate of the Claudicant, p 520). Therefore, lipid-lowering interventions should
be analyzed as secondary prevention interventions. Secondary prevention using lovastatin in
men with pretreatment cholesterol levels between 250 and 299 mgjdL (6.5-7.7 mmol/L) was
shown to be very expensive in preventing CAD.IS Only in those with at least three risk factors,
and in those with at least two risk factors including an excessively high cholesterol level (above
300 mgy'dl.), was primary prevention cost-effective in preventing CAD. Secondary prevention
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using lovastatin was demonstrated to be cost-effective in most situations, with acceptable incre-
mental cost-effectiveness ratios depending on age, pretreatment cholesterol levels, and dosage.
A related, more recent analysis demonstrated that the projected gain in quality-adjusted life-
years with secondary prevention according to the NCEP guidelines was 0.05 to 0.08/PY of
treatment. 16 The incremental gain with primary prevention in high-risk groups (compared with
secondary prevention only) was 0.014 to 0.015 QALYs/PY of treatment. Adding primary pre-
vention in moderate-risk groups added only 0.008 to 0.009 QALYs/PY of treatment.
Prevention in this context is primary in the sense that these patients have not had a prior MI or
prior stroke/TIA-that is, no known coronary or carotid disease. However, it can be considered
secondary in the sense that these patients are known to have atherosclerotic disease.
To put these numbers in perspective, treating patients for 30 years would yield a gain of 1.5 to
2.4 QALYs with secondary prevention and 0.24 to 0.45 QALYs with primary prevention. By
comparison, revascularization for CAD yields between 0.9 and 1.5 QALYs,l7 Summarizing the
numbers above, the incremental cost-effectiveness ratio of primary prevention will be roughly 5
to 10 times that of secondary prevention. In patients with IC, the cost-effectiveness of sec-
ondary prevention with a statin is approximately $40,000 per QALY gained (Euro 37,200),
which is cost-effective in the current health care environment. IS
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